Volume 9, Number 1—January 2003
Research
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Figure 1
![Schematic representation of the decision model. In panel A, the square node at the left represents the vaccination decision. The woman’s health thereafter is simulated by a Markov model. Each month, women are at risk of developing Human papillomavirus (HPV) infection, SIL (squamous intraepithelial lesions), or cervical cancer. Women who contract HPV may be infected by a low- or high-risk type. Panel B demonstrates cervical-cancer diagnosis, treatment, and natural history. Throughout a woman’s li](/eid/images/02-0168-F1.jpg)
Figure 1. Schematic representation of the decision model. In panel A, the square node at the left represents the vaccination decision. The woman’s health thereafter is simulated by a Markov model. Each month, women are at risk of developing Human papillomavirus (HPV) infection, SIL (squamous intraepithelial lesions), or cervical cancer. Women who contract HPV may be infected by a low- or high-risk type. Panel B demonstrates cervical-cancer diagnosis, treatment, and natural history. Throughout a woman’s lifetime, her HPV, SIL, or cervical cancer status can be discovered either through development of symptoms or through routine Pap tests. Panel C shows that women who undergo a Pap test may test negative or positive for SIL.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.